NEW YORK, Jan 9, 2026, 12:43 EST — Regular session
Regencell Bioscience Holdings Limited shares rose about 8.5% to $44.96 in midday trading on Friday, clawing back from an early dip. The stock has swung between $35.13 and $50.92 in the session, with more than 1.1 million shares traded.
The bounce keeps attention on RGC after a stretch of sharp moves that has been hard to pin on fresh company updates. Regencell’s investor-relations site shows its most recent press release was dated Oct. 31.
Thursday was a reminder of how quickly the shares can turn: they ended down 21.7% at $41.42 after ranging from $34 to $69 on about 3.35 million shares, according to market data. Nasdaq halt records show the stock was paused twice on Thursday morning under the limit up-limit down code, at 10:16 a.m. and 10:29 a.m. ET.
Limit up-limit down, or LULD, is a market-wide volatility guardrail. It can pause trading if prices move outside preset bands around a rolling reference price.
Separately, Bragar Eagel & Squire said on Thursday it was investigating Regencell on behalf of stockholders. The firm asked investors who suffered losses to contact it.
Regencell has also been turning up on premarket movers lists as the volatility spilled into early trading. Barron’s flagged the shares up 13.5% before the open on Thursday.
But the company is still an early-stage operation focused on developing and commercializing traditional Chinese medicine for ADHD and autism spectrum disorder, its latest annual report said. The same filing shows CEO Yat-Gai Au controls about 88.6% of the shares, a structure that can magnify price swings when trading gets crowded.
Next up, traders are watching whether the stock can hold around Thursday’s closing level near $41. Broader risk assets face a new inflation test on Tuesday, when the Labor Department is due to release December CPI data at 8:30 a.m. ET.
Related articles: Biotechnology
